May 4, 2023 | Press Releases
CUPERTINO, Calif., May 04, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
May 1, 2023 | Press Releases
Multifaceted activity of brilaroxazine supports potential for improvement in behavioral symptoms as well as accompanying neuroinflammation This proof-of-concept data supported the initial clinical development of brilaroxazine and reinforces the clinical profile...
Apr 25, 2023 | Press Releases
Virtual event on Tuesday, May 2, 2023 at 11:00am ET will feature key opinion leader (KOL) Larry Ereshefsky, PharmD, BCPP, FCCP, Chief Scientific Officer, Follow the MoleculeCUPERTINO, Calif., April 25, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH)...
Apr 20, 2023 | Press Releases
CUPERTINO, Calif., April 20, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Mar 30, 2023 | Press Releases
– Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 – – Completed majority of non-clinical and clinical prelaunch measures for brilaroxazine New Drug Application (NDA)...
